-
BioMark: 2025 Achievements & 2026 Vision
-
BioMark Diagnostics appoints James Lavender to board of directors
-
BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors
-
BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program
-
BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala
-
BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy
-
BioMark's Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial
-
BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid Biopsy
-
BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership
-
BioMark Diagnostics Announces Expansion of Its Specialty Laboratory Services in Quebec to Accommodate Increased Demand from International Partnerships
-
BioMark Diagnostics Highlights Fiscal Year 2025 Achievements and Sets Bold Strategic Milestones for 2025 - 2026
-
BioMark Diagnostics Announces Breakthrough Publication Reinforcing Leadership in AI-Powered Metabolomics for Oncology
-
BioMark Diagnostics Announces Landmark Publication Validating High Specificity and Accuracy of Its Early-Stage Lung Cancer Test
-
BioMark Diagnostics Announces Uplisting to OTCQB Venture Market

